Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2025 12:00 ET | Source: Neutrolis, Inc.

Neutrolis Presented First-in-Human Proof-of-Concept Data Validating DNASE1L3-Mediated Neutrophil Extracellular Trap (NET) Clearance as a Therapeutic Approach in Autoimmunity at American College of Rheumatology Convergence 2025

- First-in-human data validating direct targeting of NETs as a novel therapeutic approach in autoimmunity and inflammatory diseases - DNASE1L3 analogue therapy degrades NETs and results in rapid,...
October 13, 2025 15:00 ET | Source: Neutrolis, Inc.

Neutrolis Announces Late-Breaking Oral Presentation of Clinical Results at American College of Rheumatology Convergence 2025

CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Neutrolis Inc., a clinical-stage biotech company focused on targeting Neutrophil Extracellular Traps (NETs) to revolutionize the treatment of...
December 23, 2024 08:00 ET | Source: Neutrolis, Inc.

Neutrolis Licenses University of Illinois Chicago Patent to Advance Topical Dry Eye Disease Therapy Targeting NETs

CAMBRIDGE, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neutrolis Inc., a clinical stage biotech company focused on targeting Neutrophil Extracellular Traps (NETs) for the treatment of autoimmune and...
December 18, 2024 08:00 ET | Source: Neutrolis, Inc.

Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases

CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neutrolis Inc., a clinical stage biotech company focused on targeting Neutrophil Extracellular Traps (NETs) for the treatment of autoimmune and...